Curis Reports Q1 Revenue of $0, Cash Totaling $15M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 16 hours ago
0mins
Should l Buy CRIS?
Reports Q1 revenue $0, consensus $1.86M. As of March 31 Curis's cash and cash equivalents totaled $15.0M, and the Company had approximately 40.0 million shares of common stock outstanding.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRIS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRIS
Wall Street analysts forecast CRIS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.551
Low
5.00
Averages
11.00
High
17.00
Current: 0.551
Low
5.00
Averages
11.00
High
17.00
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Curis Inc Reports Q1 2026 Earnings and Study Progress
- Study Progress: Curis Inc is making steady progress in its Teykain lymphoma study, anticipating accelerated submissions in the U.S. and Europe, which could enhance its market position in treating difficult NHL subtypes.
- Financial Performance: The company reported a net loss of $24.2 million for Q1 2026, a significant increase from the previous year, primarily due to changes in the fair value of warrant liabilities related to recent financing, potentially impacting future financing capabilities.
- Recruitment Challenges: Enrollment in the PCNSL study has been described as 'lumpy,' indicating potential challenges in patient recruitment that may affect the study's timeline and outcomes.
- Future Outlook: While not currently pursuing commercial partnerships for its AML program, Curis plans to leverage existing resources to advance its studies, with expectations to fully enroll the PCNSL study by 2027, reflecting a cautiously optimistic outlook for future growth.
See More
Curis, Inc. Q1 2026 Earnings Call Insights
- Clinical Study Progress: Curis is making steady progress in its TakeAim study for primary CNS lymphoma, expecting to provide updated emavusertib clinical data in the first half of 2027, which will support accelerated submissions in the U.S. and Europe, indicating the company's strategic positioning in oncology treatment.
- Financial Loss Overview: Curis reported a net loss of $24.2 million or $1.25 per share for Q1 2026, significantly higher than the $10.6 million loss in the same period of 2025, primarily due to changes in the fair value of warrant liabilities associated with the January 2026 PIPE financing, reflecting pressure on the company's financing structure.
- R&D Expense Changes: Research and development expenses were $6.4 million in Q1, down from $8.5 million in the prior year, attributed mainly to lower employee-related and manufacturing costs, demonstrating the company's efforts in cost control.
- Funding Status and Outlook: As of March 31, 2026, Curis had cash and cash equivalents of $15 million, with anticipated gross proceeds of up to $20.2 million from the exercise of January 2026 PIPE financing warrants, which should enable operations into the second half of 2027, indicating a cautious approach to financial management.
See More
Curis Reports Q1 Earnings Miss with Strategic Cash Position
- Earnings Miss: Curis reported a Q1 GAAP EPS of -$1.25, missing expectations by $0.90, indicating challenges in profitability that could impact investor confidence and stock performance.
- Cash Position: As of March 31, 2026, Curis had $15.0 million in cash and cash equivalents, reflecting tight liquidity in the short term, necessitating careful management of operational expenditures to sustain business continuity.
- Financing Strategy: The company anticipates gross proceeds of up to $20.2 million from the exercise of January 2026 PIPE Financing Series B Warrants, which should support operations into the second half of 2027, particularly in clinical trial activities.
- Clinical Trial Goals: Curis aims for full enrollment in its PCNSL registrational study within 12-18 months while advancing its CLL proof-of-concept, which, if successful, could provide significant growth momentum for the company.
See More
Curis Reports Q1 2026 Business Update and Financial Results
- Clinical Trial Progress: Curis's emavusertib is undergoing a Phase 1/2 trial in the TakeAim Lymphoma study, aimed at treating relapsed or refractory primary CNS lymphoma in combination with ibrutinib, with orphan drug designation granted by both the FDA and EMA to support accelerated approval filings.
- Financial Performance: For the quarter ended March 31, 2026, Curis reported a net loss of $24.2 million, or $1.25 per share, an increase from a net loss of $10.6 million in the same quarter of 2025, primarily due to rising R&D and administrative expenses, with no revenues recorded this quarter.
- Funding Initiatives: Curis completed a private placement in January 2026, expected to yield up to $80.8 million in gross proceeds, including approximately $20.2 million in initial proceeds, which will be used to support future clinical trials and operations.
- Upcoming Milestones: Curis anticipates announcing the dosing of the first five patients in the TakeAim CLL study by mid-2026, with data expected in December 2026, showcasing its potential in chronic lymphocytic leukemia treatment.
See More
Curis Scheduled to Announce Q1 Earnings on May 12
- Earnings Announcement: Curis (CRIS) is set to announce its Q1 2023 earnings on May 12 after market close, with a consensus EPS estimate of -$0.29, reflecting a significant year-over-year improvement of 76.8%, indicating potential recovery in financial performance.
- Revenue Decline: The consensus revenue estimate stands at $1.86 million, representing a 21.8% year-over-year decline, suggesting that the company faces challenges in the current market environment, which may impact its short-term growth outlook.
- Clinical Study Progress: Curis aims for full enrollment in its PCNSL registrational study within the next 12 to 18 months, which will support its market position in oncology and enhance investor confidence in its growth trajectory.
- Proof-of-Concept Research: The company is advancing its proof-of-concept study for chronic lymphocytic leukemia (CLL), and successful clinical outcomes could provide Curis with new treatment options, further diversifying its product pipeline.
See More
Curis to Report Q1 2026 Financial Results on May 12
- Earnings Announcement: Curis, Inc. will report its Q1 2026 financial and operational results on May 12, 2026, at 4:00 p.m. ET, highlighting the company's latest advancements in biotechnology.
- Conference Call Details: Management will host a conference call and webcast on the same day at 4:30 p.m. ET, allowing participants to join by dialing (800)-836-8184 from the U.S. or (646)-357-8785 internationally, ensuring timely information access for investors.
- Clinical Trial Progress: Curis is conducting the TakeAim Lymphoma Phase 1/2 study evaluating emavusertib in combination with the BTK inhibitor ibrutinib for relapsed/refractory primary central nervous system lymphoma (PCNSL), demonstrating the company's ongoing commitment to cancer treatment.
- Drug Development Licensing: Curis holds the exclusive license for emavusertib, which has received Orphan Drug Designation from the FDA for treating PCNSL, AML, and MDS, indicating its potential and further solidifying the company's market position.
See More
Curis Inc Reports Q1 2026 Earnings and Study Progress
- Study Progress: Curis Inc is making steady progress in its Teykain lymphoma study, anticipating accelerated submissions in the U.S. and Europe, which could enhance its market position in treating difficult NHL subtypes.
- Financial Performance: The company reported a net loss of $24.2 million for Q1 2026, a significant increase from the previous year, primarily due to changes in the fair value of warrant liabilities related to recent financing, potentially impacting future financing capabilities.
- Recruitment Challenges: Enrollment in the PCNSL study has been described as 'lumpy,' indicating potential challenges in patient recruitment that may affect the study's timeline and outcomes.
- Future Outlook: While not currently pursuing commercial partnerships for its AML program, Curis plans to leverage existing resources to advance its studies, with expectations to fully enroll the PCNSL study by 2027, reflecting a cautiously optimistic outlook for future growth.
See More
Curis, Inc. Q1 2026 Earnings Call Insights
- Clinical Study Progress: Curis is making steady progress in its TakeAim study for primary CNS lymphoma, expecting to provide updated emavusertib clinical data in the first half of 2027, which will support accelerated submissions in the U.S. and Europe, indicating the company's strategic positioning in oncology treatment.
- Financial Loss Overview: Curis reported a net loss of $24.2 million or $1.25 per share for Q1 2026, significantly higher than the $10.6 million loss in the same period of 2025, primarily due to changes in the fair value of warrant liabilities associated with the January 2026 PIPE financing, reflecting pressure on the company's financing structure.
- R&D Expense Changes: Research and development expenses were $6.4 million in Q1, down from $8.5 million in the prior year, attributed mainly to lower employee-related and manufacturing costs, demonstrating the company's efforts in cost control.
- Funding Status and Outlook: As of March 31, 2026, Curis had cash and cash equivalents of $15 million, with anticipated gross proceeds of up to $20.2 million from the exercise of January 2026 PIPE financing warrants, which should enable operations into the second half of 2027, indicating a cautious approach to financial management.
See More
Curis Reports Q1 Earnings Miss with Strategic Cash Position
- Earnings Miss: Curis reported a Q1 GAAP EPS of -$1.25, missing expectations by $0.90, indicating challenges in profitability that could impact investor confidence and stock performance.
- Cash Position: As of March 31, 2026, Curis had $15.0 million in cash and cash equivalents, reflecting tight liquidity in the short term, necessitating careful management of operational expenditures to sustain business continuity.
- Financing Strategy: The company anticipates gross proceeds of up to $20.2 million from the exercise of January 2026 PIPE Financing Series B Warrants, which should support operations into the second half of 2027, particularly in clinical trial activities.
- Clinical Trial Goals: Curis aims for full enrollment in its PCNSL registrational study within 12-18 months while advancing its CLL proof-of-concept, which, if successful, could provide significant growth momentum for the company.
See More
Curis Reports Q1 2026 Business Update and Financial Results
- Clinical Trial Progress: Curis's emavusertib is undergoing a Phase 1/2 trial in the TakeAim Lymphoma study, aimed at treating relapsed or refractory primary CNS lymphoma in combination with ibrutinib, with orphan drug designation granted by both the FDA and EMA to support accelerated approval filings.
- Financial Performance: For the quarter ended March 31, 2026, Curis reported a net loss of $24.2 million, or $1.25 per share, an increase from a net loss of $10.6 million in the same quarter of 2025, primarily due to rising R&D and administrative expenses, with no revenues recorded this quarter.
- Funding Initiatives: Curis completed a private placement in January 2026, expected to yield up to $80.8 million in gross proceeds, including approximately $20.2 million in initial proceeds, which will be used to support future clinical trials and operations.
- Upcoming Milestones: Curis anticipates announcing the dosing of the first five patients in the TakeAim CLL study by mid-2026, with data expected in December 2026, showcasing its potential in chronic lymphocytic leukemia treatment.
See More
Curis Scheduled to Announce Q1 Earnings on May 12
- Earnings Announcement: Curis (CRIS) is set to announce its Q1 2023 earnings on May 12 after market close, with a consensus EPS estimate of -$0.29, reflecting a significant year-over-year improvement of 76.8%, indicating potential recovery in financial performance.
- Revenue Decline: The consensus revenue estimate stands at $1.86 million, representing a 21.8% year-over-year decline, suggesting that the company faces challenges in the current market environment, which may impact its short-term growth outlook.
- Clinical Study Progress: Curis aims for full enrollment in its PCNSL registrational study within the next 12 to 18 months, which will support its market position in oncology and enhance investor confidence in its growth trajectory.
- Proof-of-Concept Research: The company is advancing its proof-of-concept study for chronic lymphocytic leukemia (CLL), and successful clinical outcomes could provide Curis with new treatment options, further diversifying its product pipeline.
See More
Curis to Report Q1 2026 Financial Results on May 12
- Earnings Announcement: Curis, Inc. will report its Q1 2026 financial and operational results on May 12, 2026, at 4:00 p.m. ET, highlighting the company's latest advancements in biotechnology.
- Conference Call Details: Management will host a conference call and webcast on the same day at 4:30 p.m. ET, allowing participants to join by dialing (800)-836-8184 from the U.S. or (646)-357-8785 internationally, ensuring timely information access for investors.
- Clinical Trial Progress: Curis is conducting the TakeAim Lymphoma Phase 1/2 study evaluating emavusertib in combination with the BTK inhibitor ibrutinib for relapsed/refractory primary central nervous system lymphoma (PCNSL), demonstrating the company's ongoing commitment to cancer treatment.
- Drug Development Licensing: Curis holds the exclusive license for emavusertib, which has received Orphan Drug Designation from the FDA for treating PCNSL, AML, and MDS, indicating its potential and further solidifying the company's market position.
See More
